CVA Family Office’s Acadia Pharmaceuticals ACAD Stock Holding History

CVA Family Office’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81K	Buy	111 +32	+41%	+$704	﹤0.01%	1450
2026 Q1	$1.76K	Buy	+79	New	+$1.89K	﹤0.01%	1557
2025 Q4	–	Sell	-23	Closed	-$491	–	1290
2025 Q3	$491	Hold	23	–	–	﹤0.01%	1252
2025 Q2	$496	Sell	23 -27	-54%	-$502	﹤0.01%	1238
2025 Q1	$831	Hold	50	–	–	﹤0.01%	1149
2024 Q4	$918	Buy	+50	New	+$807	﹤0.01%	1109

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CVA Family Office's ACAD Position: Q2 2026 in Review

CVA Family Office increased its Acadia Pharmaceuticals (ACAD) stake by 41% in Q2 2026, buying an estimated $704 and bringing the position to 111 shares worth $2.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

CVA Family Office first reported a position in ACAD in Q4 2024 and has held it in 6 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

CVA Family Office held 111 shares of Acadia Pharmaceuticals worth $2.81K as of Q2 2026.
CVA Family Office bought 32 Acadia Pharmaceuticals shares in Q2 2026, an estimated $704.
Acadia Pharmaceuticals made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1450 holding.
CVA Family Office first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.